- Report
- February 2023
- 180 Pages
Global
From €5721EUR$5,950USD£4,908GBP
- Report
- November 2022
- 130 Pages
Global
From €5721EUR$5,950USD£4,908GBP
- Report
- October 2021
- 133 Pages
Global
From €2644EUR$2,750USD£2,268GBP
€5288EUR$5,500USD£4,537GBP
- Report
- November 2018
- 336 Pages
Global
From €1322EUR$1,375USD£1,134GBP
€2644EUR$2,750USD£2,268GBP
- Report
- October 2022
- 68 Pages
Global
- Report
- August 2022
- 54 Pages
Global
From €2356EUR$2,450USD£2,021GBP
- Report
- December 2020
- 164 Pages
Global
From €4760EUR$4,950USD£4,083GBP
- Report
- December 2022
- 68 Pages
Global
From €4760EUR$4,950USD£4,083GBP
- Report
- July 2020
- 118 Pages
Global
From €4760EUR$4,950USD£4,083GBP
- Report
- February 2024
- 180 Pages
From €4990EUR$5,190USD£4,281GBP
- Report
- January 2022
- 181 Pages
Global
From €3063EUR$3,185USD£2,627GBP
€4375EUR$4,550USD£3,753GBP
- Report
- April 2023
- 120 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- April 2023
- 110 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- April 2023
- 116 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- April 2023
- 200 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Report
- August 2022
- 115 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- May 2023
- 450 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- February 2018
- 15 Pages
Global
- Report
- August 2022
- 118 Pages
Global
From €4327EUR$4,500USD£3,712GBP
The Antibody Drug Conjugate (ADC) market is a subset of the biotechnology industry that focuses on the development of targeted therapies for cancer and other diseases. ADCs are composed of an antibody, a linker, and a cytotoxic drug. The antibody binds to a specific target on the surface of a cell, and the linker and drug are released when the ADC binds to the target. This allows for the delivery of a high dose of the drug to the target cell, while minimizing the damage to healthy cells.
ADCs have been used to treat a variety of cancers, including breast, ovarian, and non-small cell lung cancer. They have also been used to treat other diseases, such as autoimmune disorders and infectious diseases.
The ADC market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Seattle Genetics, ImmunoGen, Pfizer, Merck, and Novartis. Show Less Read more